Therefore, in addition to PD-L1 expression, detection of TP53 or LKB1 mutation will hopefully guide the clinical use of immune checkpoint blocking therapy for kras mutant lung adenocarcinoma. This evidence concerns the gene STK11 and lung adenocarcinoma.